• Currently, Director of Mount Sinai Heart and Board Member at Bristol-Myers Squibb

• Previously, Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart and Vascular Center

• Published several papers on SGLT1 inhibition in Heart Failure

• Currently, the Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City

• Dr. Kosiborod is a cardiologist, an internationally-recognized expert in the field of cardiometabolic disease. Dr. Kosiborod has conducted and led numerous clinical trials, many of which have had a significant impact on treatment guidelines and clinical practice

• Dr. Kosiborod’s body of work has been central to the elucidation of the impact of SGLT2 inhibition in improving cardiovascular outcomes in various clinical settings

• Currently, Professor of Medicine at University of Chicago School of Medicine; Director of American Heart Association Comprehensive Hypertension Center
• Specializes in the diagnosis and reduction of high blood pressure, particularly in complicated and refractory cases. He is also skilled in the treatment of kidney disease, with special expertise in diabetes-related kidney disease and slowing its progression
• Received the Irvine Page-Alva Bradley Lifetime Achievement Award to acknowledge his lifetime of outstanding achievements in the field of hypertension
• American Board of Internal Medicine; American Board of Internal Medicine - Nephrology; American Hypertension Specialist Certification Program

•  Currently, Chief Medical Officer, StealthCo and Director, Board of Directors of Olatec Therapeutics

• Previously, Chief Medical Officer and/or interim Chief Executive Officer of Boston Pharmaceuticals; Global Head of Translational Medicine for the Cardiovascular and Metabolic Therapeutic Areas at Novartis in Cambridge, MA 

• MD and PhD at Yale University School of Medicine

• Cardiologist at Brigham and Women’s Hospital

• Investigator in the TIMI Study Group

• Assistant Professor of Medicine at Harvard Medical School

• Primary research interests include cardiometabolic disease, heart failure, and critical care cardiology

• Currently visiting professor in the Division of Cardiology at the University of Colorado School of Medicine, as well as a faculty member of CPC Clinical Research, an Academic Research Organization affiliated with the University of Colorado Anschutz Medical Campus.

• Has held regulatory affairs leadership positions in industry, including filing five INDs for cancer therapeutics and leading interactions with worldwide regulatory agencies in multiple therapeutic areas.

• Statistical editor for the Journal of the American College of Cardiology (JACC) and JACC – Cardiovascular Interventions.